Candidiasis, Vulvovaginal Clinical Trial
Official title:
Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial
NCT number | NCT03075046 |
Other study ID # | CentroAAP |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 20, 2017 |
Est. completion date | December 2023 |
Vulvovaginal candidiasis (CVV) is an infectious process of the female genitourinary tract, an important health issue due to the high incidence and difficulties encountered in the treatment. Therefore, new therapeutic modalities are sought with the capacity to minimize drug side-effects and to reduce recurrent cases. The objective of this stufy is to evaluate the clinical and microbiological response of the 405 nm blue light emitting diode in the treatment of women with vulvovaginal candidiasis and in women with healthy gentourine treatment. A clinical trial was conducted involving 40 women, divided into two groups, the first group consisting of women with a confirmed CVV diagnosis and a second group formed by women with a healthy genitourinary tract, without symptoms and symptoms of the disease. Both groups underwent clinical evaluation and examination with endocervice collection with gynecologist before and after a session of application of the Blue Light Emitting Diode of 405 nm, lasting 4.5 minutes. There will also be an evaluation of the effects of the diary through the questionnaire answered before and after the participants' treatment. It is expected that the 405 nm blue LED will destroy the CVV fungus demonstrated by laboratory examination and also improve the signs and results analyzed by the gynecologist and participants.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 2023 |
Est. primary completion date | February 20, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - women betwen 18 and 65 years old, with clinical suspect of vulvovaginal candidiasis and with health vaginal tract Exclusion Criteria: - Women with pacemakers, with diagnosis and / or suspicion of neoplasias, cognitive deficits, neurological and / or psychiatric diseases, pregnant women and women who have used oral antibiotics, fungicides, corticosteroids and vaginal creams in the last 30 days |
Country | Name | City | State |
---|---|---|---|
Brazil | Centro de Atenção ao Assoalho Pelvico | Salvador | Ba |
Lead Sponsor | Collaborator |
---|---|
Centro de Atenção ao Assoalho Pélvico | University of Messina, Vitale SG M.D. |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of types of cells done by oncology and microflora cytology in women treated by blue light emitting diode | These exam will be done by the collect of vaginal secretion to analyse types of cells and organisms | 15 days | |
Primary | Amount of clue cells quantified by fresh citology in vaginal secretion of women treated by blue light emitting diode | These exam will be done by the collect of vaginal secretion using KOH 10% to analyse clue cells by percentage % | 5 hours | |
Primary | Value of vaginal pH measurement in women treated by blue light emitting diode | These exam will be done by the collect of vaginal secretion using a ph measuring tape to analyse the hydrogen potential in -log10 [aH+] in women treated by blue light emitting diode. It will be used the numeric scale of pH value | 30 minutes | |
Primary | Quantification of fungal colony units by the fungus culture in vaginal secretion of women treated by blue light emitting diode | These exam will be done by the collect of vaginal secretion using Colony Forming Unit CFU in women treated by blue light emitting diode | 15 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02971007 -
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
|
Phase 2 | |
Completed |
NCT02251093 -
Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis
|
Phase 3 | |
Completed |
NCT01293643 -
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
|
Phase 3 | |
Not yet recruiting |
NCT04626258 -
Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis
|
Phase 4 | |
Completed |
NCT02733432 -
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
|
Phase 2 | |
Completed |
NCT02248506 -
Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis
|
Phase 4 | |
Completed |
NCT02730494 -
Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation
|
Phase 1 | |
Completed |
NCT02180828 -
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
|
Phase 4 | |
Recruiting |
NCT04930107 -
Vulvovaginal Candidiasis in Canadian Females
|
Early Phase 1 | |
Withdrawn |
NCT03167957 -
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
|
Phase 2 | |
Recruiting |
NCT05367089 -
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
|
Phase 3 | |
Terminated |
NCT02859493 -
Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis
|
N/A | |
Completed |
NCT01891331 -
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
|
Phase 2 | |
Completed |
NCT02888197 -
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
|
N/A | |
Completed |
NCT03975569 -
Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis
|
N/A | |
Recruiting |
NCT05059145 -
A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis
|
Phase 2 |